Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 10/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.48 |
| ▸ | GGPS1 | O95749 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27616475 | 0.98 | FDPS (0.47) | FDPSSMPD1GGPS1 | |
| SCHEMBL5029032 | 0.91 | FDPS (0.45) | FDPSSMPD1 | |
| SCHEMBL7920289 | 0.91 | FDPS (0.45) | FDPSSMPD1 | |
| SCHEMBL30153590 | 0.86 | ARG1 (0.40) | — | |
| SCHEMBL10487781 | 0.83 | FDPS (0.48) | FDPSSMPD1GGPS1 | |
| SCHEMBL10874120 | 0.81 | — | — | |
| SCHEMBL4178704 | 0.81 | — | — | |
| SCHEMBL5007938 | 0.81 | — | — | |
| SCHEMBL3024369 | 0.80 | ARG2 (0.53) | FDPSSMPD1 | |
| SCHEMBL21219814 | 0.80 | ARG2 (0.53) | FDPSSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120116027-A1 | PROCESS FOR THE PURIFICATION OF HUMAN GROWTH HORMONE POLYPEPTIDES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | NOVO NORDISK A/S (DK) | 2012-05-10 | — | — | US | disclosed |
| US-20110319592-A1 | Process for the Purification of Antibodies Using Affinity Resins Comprising Specific Ligands | NOVO NORDISK A/S (DK) | 2011-12-29 | — | — | US | disclosed |
| CN-102216325-A | Method for purifying human growth hormone polypeptides using affinity resins comprising specific ligands | NOVO NORDISK AS | 2011-10-12 | — | — | CN | disclosed |
| EP-2356141-A1 | PROCESS FOR THE PURIFICATION OF HUMAN GROWTH HORMONE POLYPEPTIDES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | Novo Nordisk A/S (DK) | 2011-08-17 | — | — | EP | disclosed |
| EP-2346892-A1 | PROCESS FOR THE PURIFICATION OF ANTIBODIES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | Novo Nordisk A/S (DK) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010055135-A1 | PROCESS FOR THE PURIFICATION OF HUMAN GROWTH HORMONE POLYPEPTIDES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | NOVO NORDISK A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055136-A1 | PROCESS FOR THE PURIFICATION OF ANTIBODIES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | NOVO NORDISK A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
| EP-2166018-A2 | Antibody binding affinity ligands | Novo Nordisk A/S (DK) | 2010-03-24 | — | — | EP | disclosed |
| EP-1831243-B1 | ANTIBODY BINDING AFFINITY LIGANDS | NOVO NORDISK AS (DK) | 2010-03-17 | — | — | EP | disclosed |
| US-20080311681-A1 | Antibody Binding Affinity Ligands | VERSAMATRIX A/S (DK) | 2008-12-18 | — | — | US | disclosed |
| US-20070027113-A1 | Purine nucleoside phosphorylase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| WO-2006066598-A2 | ANTIBODY BINDING AFFINITY LIGANDS | NOVO NORDISK A/S (DK) | 2006-06-29 | — | — | WO | disclosed |
| US-20050261253-A1 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20040043973-A1 | Pharmaceutical compositions and treatment methods | BIOVIE INC. | 2004-03-04 | — | — | US | disclosed |
| US-6380410-B1 | ALKOXYLATED FATTY ACID | BASF AKTIENGESELLSCHAFT (DE) | 2002-04-30 | — | — | US | disclosed |
| US-6320064-B1 | SURFACTANTS FOR AQUEOUS CLEANER SYSTEMS FOR CLEANING NONTEXTILE MATERIAL WITH IMPROVED FAT-REMOVAL CAPACITY | BASF AKTIENGESELLSCHAFT (DE) | 2001-11-20 | — | — | US | disclosed |
| US-6204238-B1 | BASED ON EPOXIDIZED UNSATURATED FATTY ACID ESTERS OR TRIGLYCERIDES AND REACTED WITH AMINES SUCH AS HYDROXY-AND/OR AMINO-SUBSTITUTED HYDROPHILIC AMINES OR AMINO ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-20 | — | — | US | disclosed |
| US-6057283-A | REACTING AN EPOXIDIZED FATTY AMIDE WITH ATLEST A CARBOXYALKYL AMINE OR SULFOALKYL AMINE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-02 | — | — | US | disclosed |
| US-6004923-A | ANTISOILANTS; DEGREASING NONTEXTILE MATERIALS | BASF AKTIENGESELLSCHAFT (DE) | 1999-12-21 | — | — | US | disclosed |
| US-4255450-A | Use of aminohydroxy acid amides as antimicrobial substances | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 1981-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319592-A1 | Process for the Purification of Antibodies Using Affinity Resins Comprising Specific Ligands | FCGR1A, FCGR2A, FCGR3B | FDPS 3482/4885SMPD1 4679/4885GGPS1 3347/4885 |
| US-20050261253-A1 | Kinase inhibitory phosphonate analogs | PIK3CA, PNKP, PIK3CB | FDPS 846/4885SMPD1 1238/4885GGPS1 703/4885 |
| US-20120116027-A1 | PROCESS FOR THE PURIFICATION OF HUMAN GROWTH HORMONE POLYPEPTIDES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | GHRHR, GHITM, GHSR | FDPS 3771/4885SMPD1 4357/4885GGPS1 2350/4885 |
| US-20040043973-A1 | Pharmaceutical compositions and treatment methods | HSD17B1, HSD17B7, HSD17B3 | FDPS 588/4885SMPD1 2451/4885GGPS1 672/4885 |
| US-20070027113-A1 | Purine nucleoside phosphorylase inhibitory phosphonate compounds | PNP, TYMP, MTAP | FDPS 235/4885SMPD1 302/4885GGPS1 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.